Ascendis Pharma A/S (NASDAQ:ASND) will release earnings results for the third quarter, after the closing bell on Wednesday, Nov. 12.
Analysts expect the Hellerup, Denmark-based company to report a quarterly loss at 16 cents per share, versus a year-ago loss of $1.72 per share. The consensus estimate for Ascendis Pharma's quarterly revenue is $210.87 million, compared to $57.83 million a year earlier, according to data from Benzinga Pro.
On Oct. 8, Ascendis Pharma submitted marketing authorisation application to the European Medicines Agency for TransCon CNP as a treatment for children with achondroplasia.
Ascendis Pharma shares rose 2.6% to close at $201.16 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- Raymond James analyst Martin Auster initiated coverage on the stock with a Strong Buy rating and a price target of $271 on Oct. 17, 2025. This analyst has an accuracy rate of 64%.
- JP Morgan analyst Jessica Fye maintained an Overweight rating and increased the price target from $260 to $264 on Oct. 9, 2025. This analyst has an accuracy rate of 72%.
- B of A Securities analyst Tazeen Ahmad maintained a Buy rating and boosted the price target from $227 to $230 on Sept. 2, 2025. This analyst has an accuracy rate of 60%.
- Citigroup analyst David Lebowitz maintained a Buy rating and increased the price target from $243 to $290 on Aug. 8, 2025. This analyst has an accuracy rate of 66%.
- RBC Capital analyst Luca Issi maintained an Outperform rating and raised the price target from $210 to $230 on Aug. 8, 2025. This analyst has an accuracy rate of 63%.
Considering buying ASND stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
